Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuralgia 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lung Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Doxorubicin 310-propargyl-10-deazaaminopterin 3Vincristine 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Gemcitabine 2Drug Therapy 2Cyclophosphamide 2Alemtuzumab 2romidepsin 1cc-486 1belinostat 1Vitamin B 12 1Stem Cell Transplantation 1Standard of Care 1Specimen Handling 1Prednisone 1Practice Guidelines as Topic 1Melphalan 1Magnetic Resonance Spectroscopy 1Leukapheresis 1Hematopoietic Stem Cell Mobilization 1Folic Acid 1Etoposide 1Cytarabine 1Cladribine 1Carmustine 1Busulfan 1Brentuximab Vedotin 1Biopsy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, T-Cell × Vitamin B 12 × Clear all
NCT03349333 2019-10-01

A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL

Mundipharma (China) Pharmaceutical Co. Ltd

Phase 3 Completed
85 enrolled 26 charts
Lymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡